계명대학교 의학도서관 Repository

Effects of patient-tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low-density lipoprotein cholesterol in patients with type 2 diabetes

Metadata Downloads
Author(s)
Jang Won SonDong Jun KimChang Beom LeeSeungjoon OhKee-Ho SongChan Hee JungJi Oh MokJong Hwa KimMin Kyong MoonKyung Mook ChoiJae Hyoung ChoSung Hee ChoiSoo Kyung KimKang Seo ParkHye Soon KimIn Joo KimYoung Il KimHae Jin KimSang Yong KimSungrae Kim
Keimyung Author(s)
Kim, Hye Soon
Department
Dept. of Internal Medicine (내과학)
Journal Title
Journal of Diabetes Investigation
Issued Date
2013
Volume
4
Issue
5
Keyword
AtorvastatinLow-density lipoprotein cholesterolType 2 diabetes mellitus
Abstract
Aims/Introduction:

Recently, patient-tailored statin therapy was proven effective for achieving target low-density lipoprotein (LDL) cholesterol levels. It is unclear, however, whether this therapeutic modality would be effective for atherogenic lipid profiles and inflammation in patients with type 2 diabetes.


Materials and Methods:

The present study was an 8-week, multicenter, single-step titration trial of patient-tailored atorvastatin therapy (10, 20 and 40 mg) according to baseline LDL cholesterol levels in 440 patients with type 2 diabetes. We measured the LDL particle size by polyacrylamide gel electrophoresis, and used high-sensitivity C-reactive protein (hsCRP) and adiponectin as surrogate markers of inflammation.


Results:

In the intention-to-treat analysis, 91% of the patients achieved their LDL cholesterol targets (<2.6 mmol/L) at week 8. There were significant reductions at week 8 in total cholesterol, triglycerides, non-high-density lipoprotein cholesterol (HDL) cholesterol, and the total cholesterol:HDL cholesterol ratio compared with the baseline values for all of the doses. The mean LDL particle size was significantly increased, and the small, dense LDL cholesterol levels were decreased in a dose-dependent manner over the study period. In addition, the hsCRP levels were decreased in those high-risk patients with baseline hsCRP levels over 3 mg/L (P < 0.001), and the adiponectin levels tended to increase with all of the doses (P = 0.004) at 8 weeks.


Conclusions:

Patient-tailored atorvastatin therapy based on LDL cholesterol at baseline was effective in ameliorating atherogenic LDL particle size and inflammation, in addition to achieving the target LDL cholesterol level without an undesirable effect on glycemic control in patients with type 2 diabetes.
Keimyung Author(s)(Kor)
김혜순
Publisher
School of Medicine
Citation
Jang Won Son et al. (2013). Effects of patient-tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low-density lipoprotein cholesterol in patients with type 2 diabetes. Journal of Diabetes Investigation, 4(5), 466–474. doi: 10.1111/jdi.12074
Type
Article
ISSN
2040-1116
DOI
10.1111/jdi.12074
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/33775
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.